Multicenter, randomized, phase II study of neoadjuvant chemotherapy associated or not with zoledronate and atorvastatin in triple negative breast cancers - YAPPETIZER Study
Latest Information Update: 18 Jul 2024
Price :
$35 *
At a glance
- Drugs Atorvastatin (Primary) ; Zoledronic acid (Primary) ; Antineoplastics
- Indications Early breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms YAPPETIZER
- 18 Oct 2023 Status changed from active, no longer recruiting to completed.
- 28 Mar 2023 Planned End Date changed from 11 Jul 2020 to 25 Jul 2023.
- 28 Mar 2023 Status changed from recruiting to active, no longer recruiting.